Literature DB >> 22004597

Analysis of systemic inflammatory response in the carcinogenic process of uterine cervical neoplasia.

Elisa Lopes e Lages1, Andrezza Vilaça Belo, Silvia Passos Andrade, Monaliza Ângela Rocha, Gustavo Ferreira de Freitas, Rívia Mara Lamaita, Paulo Traiman, Agnaldo Lopes Silva-Filho.   

Abstract

The inflammatory response is an active process in cervical cancer and may act in the progression and/or regression of the lesion. At the site of inflammation, macrophages and neutrophils are present as well as cytokines such as TNF-α and IFN-γ. This study aims to evaluate the inflammatory response levels in women with cervical intraepithelial lesions (CIN) and with squamous cell carcinoma (SCC) of the cervix. Serum samples obtained from women without evidence of disease (n=30), with CIN (n=30) and with SCC of the cervix (n=30) were analyzed for the activities of N-acetylglucosaminidase (NAG) and myeloperoxidase (MPO) by enzymatic assay and the serum levels of TNF-α and IFN-γ by ELISA assay. The activities of NAG and MPO and the level of TNF-α were higher in women with CIN compared to the women with SCC. The levels of IFN-γ were lower in the group of women with CIN compared to the group with SCC. There was not a significant association between the degree of the CIN and the staging of the SCC of the cervix and the degree of inflammation as assessed by the levels of inflammatory markers. The inflammatory response was inversely correlated with the progression of the carcinogenic process. In the three groups, the control group, women with CIN and women with invasive SCC, there was no association between the degree of preinvasive lesions and staging of the SCC of the cervix. Copyright Â
© 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004597     DOI: 10.1016/j.biopha.2011.06.010

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.

Authors:  Sanjana Balachandra; Samuel B Kusin; Rebecca Lee; James-Michael Blackwell; Jasmin A Tiro; Lindsay G Cowell; Cheng-Ming Chiang; Shwu-Yuan Wu; Sanskriti Varma; Erika L Rivera; Helen G Mayo; Lianghao Ding; Baran D Sumer; Jayanthi S Lea; Aditya Bagrodia; Linda M Farkas; Richard Wang; Carole Fakhry; Kristina R Dahlstrom; Erich M Sturgis; Andrew T Day
Journal:  Cancer       Date:  2020-12-03       Impact factor: 6.860

2.  Quantitative Proteomic Analysis of Cervical Cancer Tissues Identifies Proteins Associated With Cancer Progression.

Authors:  Alberto Ramírez-Torres; Jeovanis Gil; Sandra Contreras; Graciela Ramírez; Heriberto A Valencia-González; Emmanuel Salazar-Bustamante; Leopoldo Gómez-Caudillo; Alejandro García-Carranca; Sergio Encarnación-Guevara
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

3.  Tumor specificity of WNT ligands and receptors reveals universal squamous cell carcinoma oncogenes.

Authors:  Cheng Chen; Lunan Luo; Changling Xu; Xia Yang; Ting Liu; Jingyue Luo; Wen Shi; Lu Yang; Yi Zheng; Jing Yang
Journal:  BMC Cancer       Date:  2022-07-19       Impact factor: 4.638

4.  Prognostic Values of Systemic Inflammation Response (SIR) Parameters in Resectable Cervical Cancer.

Authors:  Wen-Jie Wang; Ying Li; Jie Zhu; Min-Jie Gao; Jian-Ping Shi; Yue-Qing Huang
Journal:  Dose Response       Date:  2019-02-26       Impact factor: 2.658

5.  HPV-related methylation-based reclassification and risk stratification of cervical cancer.

Authors:  Si Yang; Ying Wu; Shuqian Wang; Peng Xu; Yujiao Deng; Meng Wang; Kang Liu; Tian Tian; Yuyao Zhu; Na Li; Linghui Zhou; Zhijun Dai; Huafeng Kang
Journal:  Mol Oncol       Date:  2020-06-02       Impact factor: 6.603

6.  Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study.

Authors:  K Torres-Poveda; A I Burguete-García; M Bahena-Román; R Méndez-Martínez; M A Zurita-Díaz; G López-Estrada; K Delgado-Romero; O Peralta-Zaragoza; V H Bermúdez-Morales; D Cantú; A García-Carrancá; V Madrid-Marina
Journal:  BMC Cancer       Date:  2016-05-24       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.